Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 12-Month High - Should You Buy?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $57.18 and last traded at $57.05, with a volume of 228659 shares traded. The stock had previously closed at $54.50.

Analyst Ratings Changes

TARS has been the topic of a number of analyst reports. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Finally, Barclays lifted their price target on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a report on Monday, January 27th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -13.90 and a beta of 1.01. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm has a fifty day simple moving average of $52.01 and a 200-day simple moving average of $40.87.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in TARS. R Squared Ltd bought a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $53,000. FMR LLC raised its stake in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after buying an additional 3,537 shares during the last quarter. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $207,000. Victory Capital Management Inc. bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $223,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth $227,000. Institutional investors and hedge funds own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.